Citations

Clear

750 citation(s) found for "Lowe, Val".

P1‐197: AMYLOID BETA EFFECTS ON INSULIN PERMEABILITY FROM PLASMA TO BRAIN MEASURED BY I‐125 INSULIN SPECT IN APP/PS1 MICE
Swaminathan, Suresh Kumar, Sarma, Vidur , Ahlschwede, Kristen M. , Bruinsma, Tyler J. , Curran, Geoffry L., Decklever, Teresa, Lowe, Val J. , Min, Hoon-Ki Paul , Kandimalla, Karunya K.

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_6 | Pages: No page available

10.1016/j.jalz.2018.06.201 Get It

Multisite study of the relationships between antemortem [ 11 C]PIB‐PET Centiloid values and postmortem measures
Joie, Renaud La , Ayakta, Nagehan , Borys, Ewa, Boxer, Adam L. , DeCarli, Charles , Doré, Vincent , Grinberg, Lea T. , Huang, Eric J. , Hwang, Ji‐Hye , Ikonomović, Miloš D. , Jack, Clifford R. , Jagust, William J. , Jin, Lee‐Way, Klunk, William E. , Kofler, Julia , Lesman‐Segev, Orit H. , Lockhart, Samuel N. , Lowe, Val J. , Masters, Colin L. , Mathis, Chester A. , McLean, Catriona , Miller, Bruce L. , Mungas, Daniel, O’Neil, James P. , Olichney, John , Parisi, Joseph E., Petersen, Ronald C. , Rosen, Howard J. , Vemuri, Prashanthi , Villemagne, Victor L. , Murray, Melissa E. , Rabinovici, Gil D. , DeCarli, Charles , Jack, Clifford R , Vemuri, Prashanthi , Miller, Bruce L , Murray, Melissa E , Masters, Colin L , La Joie, Renaud , Grinberg, Lea , Rabinovici, Gil D , Seeley, William W. , Rowe, Christopher Cleon , Spina, Salvatore , Mclean, Catriona , Doré, Vincent

Mayo Clinic

Alzheimer's & Dementia | October 20, 2018 | Volume: 15 | Issue: 2 | Pages: 205-216

10.1016/j.jalz.2018.09.001 | PMID 30347188 Get It

Abstract Introduction We sought to establish the relationships between standard postmortem measures of AD neuropathology and antemortem [ 11 C]PIB–positron emission tomography ([ 11 C]PIB‐PET) analyzed with the Centiloid (CL) method, a standardized scale for Aβ‐PET quantification. Methods Four centers contributed 179 participants encompassing a broad range of clinical diagnoses, PET data, and autopsy findings. Results CL values increased with each CERAD neuritic plaque score increment (median −3 CL for no plaques and 92 CL for frequent plaques) and nonlinearly with Thal Aβ phases (increases were detected starting at phase 2) with overlap between scores/phases. PET‐pathology associations were comparable across sites and unchanged when restricting the analyses to the 56 patients who died within 2 years of PET. A threshold of 12.2 CL detected CERAD moderate‐to‐frequent neuritic plaques (area under the curve = 0.910, sensitivity = 89.2%, specificity = 86.4%), whereas 24.4 CL identified intermediate‐to‐high AD neuropathological changes (area under the curve = 0.894, sensitivity = 84.1%, specificity = 87.9%). Discussion Our study demonstrated the robustness of a multisite Centiloid [ 11 C]PIB‐PET study and established a range of pathology‐based CL thresholds.
Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging
Vemuri, Prashanthi , Lesnick, Timothy G. , Przybelski, Scott A. , Graff‐Radford, Jonathan, Reid, Robert I. , Lowe, Val J. , Zuk, Samantha M., Senjem, Matthew L. , Schwarz, Christopher G. , Gunter, Jeffrey L. , Kantarci, Kejal , Mielke, Michelle M. , Petersen, Ronald C. , Jack, Clifford R. , Jack, Clifford R , Schwarz, Christopher G , Mielke, Michelle M , Reid, Robert I , Vemuri, Prashanthi , Senjem, Matthew L , Kantarci, Kejal , Graff‐Radford, Jonathan , Machulda, Mary M. , Knopman, David S.

Mayo Clinic

Annals of Neurology | September 28, 2018 | Volume: 84 | Issue: 5 | Pages: 705-716

10.1002/ana.25346 | PMID 30264411 Get It

ObjectiveRecent availability of amyloid and tau positron emission tomography (PET) has provided us with a unique opportunity to measure the association of systemic vascular health with brain health after accounting for the impact of Alzheimer disease (AD) pathologies. We wanted to quantify early cerebrovascular health–related magnetic resonance imaging brain measures (structure, perfusion, microstructural integrity) and evaluate their utility as a biomarker for cerebrovascular health.MethodsWe used 2 independent samples (discovery, n = 390; validation, n = 1,035) of individuals, aged ≥ 60 years, along the cognitive continuum with imaging from the population‐based sample of Mayo Clinic Study of Aging. We ascertained vascular health by summing up recently existing cardiovascular and metabolic conditions (CMC) from health care records (hypertension, hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke). Using multiple regression models, we quantified associations between CMC and brain health after accounting for age, sex, education/occupation, and AD burden (from amyloid and tau PET).ResultsSystemic vascular health was associated with medial temporal lobe thinning, widespread cerebral hypoperfusion, and loss of microstructural integrity in several white matter tracts including the corpus callosum and fornix. Further investigations suggested that microstructural integrity of the genu of the corpus callosum was suitable for assessing prodromal cerebrovascular health, had similar distributions in the discovery and independent validation datasets, and predicted cognitive performance above and beyond amyloid deposition.InterpretationSystemic vascular health has significant impact on brain structure and function. Quantifying prodromal cerebrovascular health–related brain measures that are independent of AD pathology–related changes has great utility for cognitive aging. Ann Neurol 2018;84:713–724
Statins and Brain Health: Alzheimer’s Disease and Cerebrovascular Disease Biomarkers in Older Adults
Przybelski, Scott A. , Graff‐Radford, Jonathan , Castillo, Anna , Lowe, Val J. , Mielke, Michelle M. , Roberts, Rosebud O., Jack, Clifford R. , Petersen, Ronald C. , Vemuri, Prashanthi , Castillo, Anna M, Jack, Clifford R , Mielke, Michelle M , Vemuri, Prashanthi , Castillo, Anna M , Ramanan, Vijay K. , Reid, Robert I. , Knopman, David S.

Mayo Clinic

Journal of Alzheimer’s Disease | August 24, 2018 | Volume: 65 | Issue: 4 | Pages: 1345-1352

10.3233/jad-180446 | PMID 30149450 Get It

Background: Statins have been proposed to reduce the risk of Alzheimer’s disease (AD). Objective: Assess whether long-term statin use was associated with neuroimaging biomarkers of aging and dementia. Methods: Methods: We analyzed neuroimaging biomarkers in 1,160 individuals aged 65+ from the Mayo Clinic Study of Aging, a population-based prospective longitudinal study of cognitive aging. Results: Statin-treated (5+ years of therapy) individuals had greater burden of mid-and late-life cardiovascular disease ( p < 0.001) than statin-untreated (≤3 months) individuals. Lower fractional anisotropy in the genu of the corpus callosum, an early marker of cerebrovascular disease, was associated with long-term statin exposure ( p < 0.035). No significant associations were identified between long-term statin exposure and cerebral amyloid or tau burden, AD pattern neurodegeneration, or white matter hyperintensity burden. Conclusions: Long-term statin therapy was not associated with differences in AD biomarkers. Individuals with long-term statin exposure had worse white matter integrity in the genu of the corpus callosum, consistent with the coexistence of higher cerebrovascular risk factor burden in this group.
The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons
Vassilaki, Maria , Aakre, Jeremiah A. , Kremers, Walter K. , Geda, Yonas E. , Alhurani, Rabe E., Dutt, Taru , Vemuri, Prashanthi , Coloma, Preciosa M. , Schäuble, Barbara, Lowe, Val J. , Jack, Clifford R. , Petersen, Ronald C. , Roberts, Rosebud O., Jack, Clifford R , Vemuri, Prashanthi , Geda, Yonas E , Kremers, Walter K , Mielke, Michelle M. , Machulda, Mary M. , Knopman, David S.

Mayo Clinic

The Journals of Gerontology: Series A | August 13, 2018 | Volume: 74 | Issue: 6 | Pages: 877-883

10.1093/gerona/gly149 | PMID 30124772 Get It

Your brain scan may be a reflection of your genes
Lowe, Val J. , Kandimalla, Karunya K. , Kandimalla, Karunya K , Kalari, Krishna R.

Mayo Clinic

Brain | August 1, 2018 | Volume: 141 | Issue: 9 | Pages: 2539-2541

10.1093/brain/awy226 | PMID 30169591 Get It

Tau uptake in agrammatic primary progressive aphasia with and without apraxia of speech
Utianski, Rene L. , Whitwell, Jennifer L. , Botha, Hugo , Senjem, Matthew L. , Petersen, Ronald C. , Jack, Clifford R. , Lowe, Val J. , Josephs, Keith A. , Utianski, Rene L , Jack, Clifford R , Senjem, Matthew L , Botha, Hugo , Schwarz, Christopher G. , Duffy, Joseph R. , Clark, Heather M. , Machulda, Mary M. , Knopman, David S.

Mayo Clinic

European Journal of Neurology | June 23, 2018 | Volume: 25 | Issue: 11 | Pages: 1352-1357

10.1111/ene.13733 | PMID 29935044 Get It

Background and purposeThe non‐fluent/agrammatic variant of primary progressive aphasia (agPPA) is a heterogeneous diagnosis wherein some individuals have apraxia of speech (AOS). When agPPA includes AOS, a tauopathy is the likely underlying pathology. Recently, [18F]AV‐1451 was developed for the in‐vivo assessment of tau. In this study, we compared patterns of tau tracer uptake in patients with agPPA with and without AOS.MethodsNine patients with agPPA (four without AOS) underwent tau positron emission tomography imaging with [18F]AV‐1451. Uptake of [18F]AV‐1451 was assessed as cortical to cerebellar crus ratio (standard uptake value ratio) in cortical regions of interest measured using the MCALT atlas and compared voxel‐wise in SPM12. Each patient was age‐ and sex‐matched to three controls.ResultsThe agPPA without AOS showed uptake in the left frontal and temporal lobes, whereas agPPA with AOS showed uptake in the bilateral supplementary motor areas, frontal lobes, precuneus and precentral gyrus relative to controls. The left precentral gyrus had uptake in agPPA with AOS relative to those without AOS.ConclusionsThis cross‐sectional study suggests that [18F]AV‐1451 uptake in the precentral gyrus is implicated in AOS in agPPA.
Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers
Vassilaki, Maria , Aakre, Jeremiah A. , Syrjanen, Jeremy A. , Mielke, Michelle M. , Geda, Yonas E. , Kremers, Walter K. , Alhurani, Rabe E., Staubo, Sara C., Petersen, Ronald C. , Lowe, Val J. , Jack, Clifford R. , Roberts, Rosebud O., Jack, Clifford R , Mielke, Michelle M , Geda, Yonas E , Machulda, Mary M. , Knopman, David S. , Kremers, Walter K

Mayo Clinic

Journal of Alzheimer’s Disease | June 8, 2018 | Volume: 64 | Issue: 1 | Pages: 281-290

10.3233/jad-171121 | PMID 29889074 Get It

Background: There is accumulating evidence suggesting that diet may play a role in preventing or delaying cognitive decline and dementia, but the underlying biological mechanisms are not well understood. Objectives: To examine the cross-sectional associations of the Mediterranean diet (MeDi) and its components with 11 C-PiB-PET scan measures of amyloid-β (Aβ) deposition. Methods: The study consisted of 278 Mayo Clinic Study of Aging participants 70+ years old, who were cognitively unimpaired (CU) at the time of completion of the Food Frequency Questionnaire (FFQ) and when they underwent PET imaging. Adherence to the MeDi was assessed by computing the MeDi score for each participant. All scans were performed after the FFQ completion; median [IQR] time between FFQ and Aβ PET was 3.5 (1.4) years. Z-scores were created for component, macro- and micronutrients measured. Linear and logistic regression models were adjusted for age, sex, education, apolipoprotein E (APOE) ɛ4 allele carrier status, time interval between the FFQ completion and PET scan, and total energy intake. Results: Participants’ median age at FFQ was 77.7 years (55.8% men; 26.6% with an APOE ɛ4 allele). Higher MeDi score (linear regression slope (beta):–0.035, p = 0.012; per standard deviation increase), vegetable intake (beta:–0.043, p = 0.002), intake of vitamin A (beta:–0.041, p = 0.003) or β-carotene (beta: –0.039, p = 0.005) from food sources and moderate alcohol consumption (beta: –0.074, p = 0.03) were associated with lower 11 C-PiB standardized uptake value ratio. Conclusion: Findings are consistent with previous studies suggesting that higher adherence to a MeDi pattern and higher vegetable consumption are associated with better neuroimaging biomarker profile. Prospective studies are needed to validate current findings.
Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type
Whitwell, Jennifer L., Kantarci, Kejal , Weigand, Stephen D. , Lundt, Emily S. , Gunter, Jeffrey L. , Spychalla, Anthony J., Drubach, Daniel A., Petersen, Ronald C. , Lowe, Val J. , Josephs, Keith A. , Strand, Edythe A. , Kantarci, Kejal , Whitwell, Jennifer , Duffy, Joseph R. , Machulda, Mary M. , Jack, Clifford R. , Lundt, Emily S

Mayo Clinic

Journal of Alzheimer’s Disease | June 4, 2018 | Volume: 45 | Issue: 4 | Pages: 1109-1117

10.3233/jad-142628 | PMID 25649655 Get It

Background: Microbleeds in the brain have been shown to occur in Alzheimer’s disease (AD), affecting approximately a third of subjects that present with typical dementia of the Alzheimer’s type (DAT). However, little is known about the frequency or distribution of microbleeds in subjects with AD that present with atypical clinical presentations. Objective: To determine whether the frequency and regional distribution of microbleeds in atypical AD differs from that observed in subjects with DAT, and to determine whether microbleeds in atypical AD are associated with age, demographics, or cognitive impairment. Methods: Fifty-five subjects with amyloid-β deposition on Pittsburgh compound B (PiB) PET who presented with predominant language (n = 37) or visuospatial/perceptual (n = 18) deficits underwent T2*weighted MRI. These subjects were compared to 41 PiB-positive subjects with DAT. Microbleeds were identified and assigned a lobar location. Results: The proportion of subjects with microbleeds did not differ between atypical AD (42%) and DAT (32%). However, atypical AD had larger numbers of microbleeds than DAT. In addition, the topographic distribution of microbleeds differed between atypical AD and DAT, with atypical AD showing the highest density of microbleeds in the frontal lobes. Among atypical AD, number of microbleeds was associated with age, but not gender or cognition. Microbleeds were more common in subjects with language (51%) versus visuospatial/perceptual deficits (22%). Conclusions: Microbleeds are relatively common in both DAT and atypical AD, although atypical AD subjects appear to be at particular risk for developing large numbers of microbleeds and for developing microbleeds in the frontal lobe.